Of note, the National Comprehensive Cancer Network (NCCN) management guiding principles have recommended immunotherapy-based combination regimens as front-line management for individuals with advanced NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations (Ettinger et al. 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.